Document is current

Article History

Received: 18 February 2025

Accepted: 10 August 2025

First Online: 31 August 2025

Declarations

:

: The SYMPHONY consortium, which aims to orchestrate personalised treatment in patients with bleeding disorders, is a unique collaboration between patients, healthcare professionals, and translational and fundamental researchers specialised in iBDs, as well as experts from multiple disciplines. It aims to identify the best treatment choice for each individual based on the bleeding phenotype. To achieve this goal, work packages (WPs) have been organised according to three themes, for example Diagnostics (WPs 3&4), Treatment (WPs 5-9) and Fundamental Research (WPs 10-12). This research receives funding from the Netherlands Organization for Scientific Research (NWO) in the framework of the NWA-ORC call grant agreement NWA.1160.18.038. Principal investigator: Prof. M.H. Cnossen. Project manager: Dr. S.H. Reitsma. More information: . Beneficiaries of the SYMPHONY consortium: Erasmus University Medical Center-Sophia Children’s Hospital, project leadership and coordination; Sanquin Diagnostics; Sanquin Research; Amsterdam University Medical Centers; University Medical Center Groningen; University Medical Center Utrecht; Leiden University Medical Center; Radboud University Medical Center; Netherlands Society of Hemophilia Patients (NVHP); Netherlands Society for Thrombosis and Hemostasis (NVTH); Bayer B.V., CSL Behring B.V., Swedish Orphan Biovitrum (Belgium) BVBA/SPRL. Additional beneficiaries that are not included in the SYMPHONY consortium funding parallel projects are: Novonordisk (OPTI-CLOT TARGET), Roche (Partitura), Stichting Haemophilia (patient-reported outcomes project).

: Marjon H. Cnossen has received investigator-initiated research and travel grants as well as speaker fees over the years from the Netherlands Organization for Scientific Research (NWO) and Netherlands National Research Agenda (NWA), the Netherlands Organization for Health Research and Development (ZonMw), the Dutch Innovatiefonds Zorgverzekeraars, Stichting Haemophilia, Baxter/Baxalta/Shire/ Takeda, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Roche and Nordic Pharma, and for serving as a steering board member for Roche, Bayer and Novartis. All grants and fees go to the Erasmus MC as an institution. She is a coordinator of Erasmus MC as a Health Care Provider within the European Reference Network for rare hematological diseases EuroBloodNet and a (co)leader of the local Erasmus MC Expert Centers for Rare Bleeding Disorders and Sickle Cell and Thalassemia Comprehensive Care Center. Renske M.T. Ten Ham is the author of one of the studies included in this review. Diaz M. Prameyllawati and Hester F. Lingsma have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Not applicable.

: The complete search strategy for each database is detailed in Table 1 of the ESM. The data extraction table for each population type is included within this article.

: Not applicable.

: Concept and design: DMP, HFL, MHC, RMTTH; reviewer: DMP, RMTTH; data extraction: DMP; analysis and interpretation of data: DMP, RMTTH; drafting of the manuscript: DMP, HFL, MHC, RMTTH; critical revision of paper for important intellectual content: HFL, MHC, RMTTH; obtaining funding: MHC; administrative, technical or logistic support: HF, MHC, RMTTH; supervision: HFL, MHC, RMTTH.